Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study)

Rena Okuno-Ito, Masaaki Yamamoto, Yasunori Sato, Toru Serizawa, Jun Kawagishi, Takashi Shuto, Shoji Yomo, Atsuya Akabane, Kyoko Aoyagi, Takuya Kawabe, Yasuhiro Kikuchi, Kiyoshi Nakasaki, Masazumi Gondo, Yoshinori Higuchi, Toru Takebayashi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background and purpose: The Renal Graded Prognostic Assessment (GPA) is relatively new and has not been sufficiently validated using a different dataset. We thus developed a new grading index, the Renal Brain Metastasis Score (Renal-BMS). Materials and methods: Using our dataset including 262 renal cancer patients with brain metastases (BMs) undergoing stereotactic radiosurgery (SRS) (test series), we validity tested the Renal-GPA. Next, we applied clinical factor-survival analysis to the test series and thereby developed the Renal-BMS. This system was then validated using another series of 352 patients independently undergoing SRS at nine gamma knife facilities in Japan (verification series). Results: Using the test series, with the Renal-GPA, 95% confidence intervals (CIs) of the post-SRS median survival times (MSTs) overlapped between pairs of neighboring subgroups. Among various pre-SRS clinical factors of the test series, six were highly associated with overall survival. Therefore, we assigned scores for six factors, i.e., “KPS ≥ 80%/<80% (0/3)”, “tumor numbers 1–4/≥5 (score; 0/2)”, “controlled primary cancer/not (0/2)”, “existing extra-cerebral metastases/not (0/3)”, “blood hemoglobin ≥ 11.0/<11.0 g/dl (0/1)” and “interval from primary cancer to SRS ≥ 5/<5 years (0/1)”. Patients were categorized into three subgroups according to the sum of scores, i.e., 0–4, 5–8 and 9–12. In the test and verification series, post-SRS MSTs differed significantly (p < 0.0001) with no overlaps of 95% CIs among the three subgroups. Conclusions: The Renal BMS has the potential to be very useful to physicians selecting among aggressive treatment modalities for renal cancer patients with BMs.

Original languageEnglish
Pages (from-to)69-75
Number of pages7
JournalClinical and Translational Radiation Oncology
Volume32
DOIs
Publication statusPublished - 2022 Jan

Keywords

  • Brain metastases
  • Prognostic grade
  • Renal cancer
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study)'. Together they form a unique fingerprint.

Cite this